Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Moik, F; Riedl, JM; Ay, C.
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Ann Oncol. 2024; 35(3):327
Doi: 10.1016/j.annonc.2023.11.007
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Moik Florian
- Co-authors Med Uni Graz
- Riedl Jakob
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Carcinoma, Non-Small-Cell Lung - drug therapy, genetics
- Aniline Compounds - therapeutic use
- Lung Neoplasms - drug therapy, genetics
- Disease Progression - administration & dosage
- ErbB Receptors - genetics
- Mutation - administration & dosage
- Protein Kinase Inhibitors - therapeutic use
- Antibodies, Bispecific - administration & dosage
- Morpholines - administration & dosage
- Acrylamides - administration & dosage
- Pyrimidines - administration & dosage
- Indoles - administration & dosage
- Pyrazoles - administration & dosage